Tesamorelin is a stabilized synthetic analog of growth-hormone-releasing hormone (GHRH) studied in laboratory research for its activity at the GHRH receptor and GH-axis signaling pathways. All information on this page is for in-vitro laboratory research use only. Not for human consumption.
GHRH receptor signaling is a well-characterized pathway in which the hypothalamic peptide GHRH binds the somatotroph GHRH-R, activating the Gαs/cAMP/PKA cascade and stimulating pulsatile GH secretion. Tesamorelin's trans-3-hexenoyl modification at the N-terminus confers improved plasma stability relative to native GHRH(1–44) without altering the receptor-binding pharmacophore, making it a useful tool compound for in-vitro GHRH-R studies, receptor-binding assays, and mechanistic work on the GH axis.
Published clinical research from the LIPO-010 and LIPO-011 trials characterized its GH-secretion and adipose-metabolism effects in human subjects at the IND level. That body of literature provides reference context for laboratory researchers designing in-vitro assay conditions. All Excalibur Peptides product is for in-vitro research use only and is not supplied for clinical or therapeutic administration.
Tesamorelin is a stabilized synthetic analog of growth-hormone-releasing hormone (GHRH) used in laboratory research as a tool compound for studying the GHRH receptor and growth-hormone secretion pathways.
Both are GHRH analogs. Sermorelin corresponds to the first 29 amino acids of GHRH, while tesamorelin is a full-length GHRH(1-44) analog with an N-terminal trans-3-hexenoyl modification that improves plasma stability in research models.
Tesamorelin has an approximate molecular weight of 5135.8 g/mol, consistent with a 44-residue GHRH analog carrying a trans-3-hexenoyl N-terminal modification.
No. Every compound in this catalog, including tesamorelin, is supplied strictly for in-vitro laboratory research use only. It is not for human consumption, injection, or ingestion.